Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Vertex Pharmaceuticals Inc., consolidated statement of comprehensive income
US$ in thousands
12 months ended
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Net income (loss)
1,176,810
2,087,103
91,635
(84,031)
(588,181)
Unrealized holding gains (losses) on marketable securities, net of tax
1,039
58
6,954
17,395
249
Unrealized gains (losses) on foreign currency forward contracts, net of tax
(14,003)
27,438
(26,530)
7,736
1,767
Foreign currency translation adjustment
10,332
8,855
(13,169)
(5,782)
(1,109)
Changes in other comprehensive income (loss)
(2,632)
36,351
(32,745)
19,349
907
Comprehensive income (loss)
1,174,178
2,123,454
58,890
(64,682)
(587,274)
Comprehensive (income) loss attributable to noncontrolling interest
—
9,793
171,849
(28,021)
31,847
Comprehensive income (loss) attributable to Vertex
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Vertex Pharmaceuticals Inc.’s net income (loss) attributable to Vertex increased from 2017 to 2018 but then slightly decreased from 2018 to 2019 not reaching 2017 level.
Comprehensive income (loss) attributable to Vertex
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Vertex Pharmaceuticals Inc.’s comprehensive income (loss) attributable to Vertex increased from 2017 to 2018 but then slightly decreased from 2018 to 2019 not reaching 2017 level.
